Medytox(086900) said on the 10th that it posted 68.7 billion won in consolidation sales and 4.8 billion won in operating profit in the second quarter this year. Sales rose 11% from a year earlier, but operating profit fell 25%.
Botox (botulinum toxin) and the submental fat-dissolving injection NewVisu maintained a steady trend. Botox is a toxic protein extracted from the botulinum bacterium. When injected into the skin, it paralyzes muscles and temporarily smooths fine wrinkles.
Filler sales fell as competition in the domestic market intensified. The company noted that expense increased as it expanded other businesses. The company plans to expand academic programs for medical staff in the second half.
A Medytox official said the company would strengthen its competitiveness in overseas business.